A Phase II clinical trial demonstrated that combination of pemetrexed and gefitinib was more prominent in improving PFS compared with gefitinib alone in patients with advanced nonsquamous NSCLC and activating EGFR mutations [7]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.